BACKGROUND: We previously demonstrated upregulation of c-myc, survivin, and cyclin D1 in CD34+ bone marrow mononuclear cells (BMMNCs) of patients with trisomy 8 and monosomy 7 myelodysplastic syndromes (MDS). "Knockdown" of cyclin D1 by RNA interference decreased trisomy 8 cell growth, suggesting that this might be a therapeutic target in MDS. EXPERIMENTAL DESIGN: We performed preclinical studies using BMMNCs from patients with MDS and AML to examine the effects of the styryl sulfone ON 01910.Na on cyclin D1 accumulation, aneuploidy, and CD34+ blast percentage. We next treated twelve patients with higher risk MDS and two trisomy 8 AML patients with ON 01910.Na on a phase I clinical protocol (NCT00533416). RESULTS: ON 01910.Na inhibited cyclin D1 expression, and was selectively toxic to trisomy 8 cells in vitro. Flow cytometry studies demonstrated increased mature CD15+ myeloid cells and decreased CD34+ blasts. Three patients treated with ON 01910.Na on a clinical had decreased bone marrow blasts by ≥ 50%, and three patients had hematologic improvements, one of which was sustained for 33 months. Patients with hematologic responses to ON 01910.Na had decreased cyclin D1 expression in their CD34+ cells. CONCLUSIONS: The preclinical results and responses of patients on a clinical trial warrant further investigation of ON 01910.Na as a potential novel targeted therapy for higher risk MDS patients. Published by Elsevier Ltd.
BACKGROUND: We previously demonstrated upregulation of c-myc, survivin, and cyclin D1 in CD34+ bone marrow mononuclear cells (BMMNCs) of patients with trisomy 8 and monosomy 7 myelodysplastic syndromes (MDS). "Knockdown" of cyclin D1 by RNA interference decreased trisomy 8 cell growth, suggesting that this might be a therapeutic target in MDS. EXPERIMENTAL DESIGN: We performed preclinical studies using BMMNCs from patients with MDS and AML to examine the effects of the styryl sulfone ON 01910.Na on cyclin D1 accumulation, aneuploidy, and CD34+ blast percentage. We next treated twelve patients with higher risk MDS and two trisomy 8 AMLpatients with ON 01910.Na on a phase I clinical protocol (NCT00533416). RESULTS: ON 01910.Na inhibited cyclin D1 expression, and was selectively toxic to trisomy 8 cells in vitro. Flow cytometry studies demonstrated increased mature CD15+ myeloid cells and decreased CD34+ blasts. Three patients treated with ON 01910.Na on a clinical had decreased bone marrow blasts by ≥ 50%, and three patients had hematologic improvements, one of which was sustained for 33 months. Patients with hematologic responses to ON 01910.Na had decreased cyclin D1 expression in their CD34+ cells. CONCLUSIONS: The preclinical results and responses of patients on a clinical trial warrant further investigation of ON 01910.Na as a potential novel targeted therapy for higher risk MDSpatients. Published by Elsevier Ltd.
Authors: Elaine M Sloand; Monika Fuhrer; Keyvan Keyvanfar; Lori Mainwaring; Jaroslaw Maciejewski; Yu Wang; Sarah Johnson; A John Barrett; Neal S Young Journal: Br J Haematol Date: 2003-10 Impact factor: 6.998
Authors: Mahesh Seetharam; Alice C Fan; Mai Tran; Liwen Xu; John P Renschler; Dean W Felsher; Kunju Sridhar; Francois Wilhelm; Peter L Greenberg Journal: Leuk Res Date: 2011-09-14 Impact factor: 3.156
Authors: P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett Journal: Blood Date: 1997-03-15 Impact factor: 22.113
Authors: Alan List; Sandy Kurtin; Denise J Roe; Andrew Buresh; Daruka Mahadevan; Deborah Fuchs; Lisa Rimsza; Ruth Heaton; Robert Knight; Jerome B Zeldis Journal: N Engl J Med Date: 2005-02-10 Impact factor: 91.245
Authors: R Bortul; P L Tazzari; A Cappellini; G Tabellini; A M Billi; R Bareggi; L Manzoli; L Cocco; A M Martelli Journal: Leukemia Date: 2003-02 Impact factor: 11.528
Authors: E Beillard; N Pallisgaard; V H J van der Velden; W Bi; R Dee; E van der Schoot; E Delabesse; E Macintyre; E Gottardi; G Saglio; F Watzinger; T Lion; J J M van Dongen; P Hokland; J Gabert Journal: Leukemia Date: 2003-12 Impact factor: 11.528
Authors: Frank El-Ouriaghli; Elaine Sloand; Lori Mainwaring; Hiroshi Fujiwara; Keyvan Keyvanfar; J Joseph Melenhorst; Katayoun Rezvani; Giuseppe Sconocchia; Scott Solomon; Nancy Hensel; A John Barrett Journal: Blood Date: 2003-07-31 Impact factor: 22.113
Authors: Xiaoping Zhang; Hua Lv; Qingyu Zhou; Rana Elkholi; Jerry E Chipuk; M V Ramana Reddy; E Premkumar Reddy; James M Gallo Journal: Mol Cancer Ther Date: 2014-02-25 Impact factor: 6.261
Authors: Venkat R Pallela; Muralidhar R Mallireddigari; Stephen C Cosenza; Balaiah Akula; D R C Venkata Subbaiah; E Premkumar Reddy; M V Ramana Reddy Journal: Org Biomol Chem Date: 2013-02-06 Impact factor: 3.876
Authors: Takao Ohnuma; Deborah Lehrer; Chen Ren; Sool Yeon Cho; Manoj Maniar; Lewis Silverman; Max Sung; Herbert F Gretz; Vladimir Benisovich; Shyamala Navada; Eugene Akahoho; Eric Wilck; David R Taft; John Roboz; Francois Wilhelm; James F Holland Journal: Am J Cancer Res Date: 2013-06-20 Impact factor: 6.166
Authors: Rami S Komrokji; Azra Raza; Jeffrey E Lancet; Chen Ren; David Taft; Manoj Maniar; Francois Wilhelm; Alan F List Journal: Br J Haematol Date: 2013-06-21 Impact factor: 6.998